CoreCap Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

CoreCap Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.32K	Buy	23 +15	+188%	+$822	﹤0.01%	2635
2026 Q1	$452	Hold	8	–	–	﹤0.01%	2667
2025 Q4	$475	Sell	8 -1	-11%	-$54	﹤0.01%	2710
2025 Q3	$487	Hold	9	–	–	﹤0.01%	2571
2025 Q2	$495	Sell	9 -5,262	-100%	-$310K	﹤0.01%	2512
2025 Q1	$373K	Buy	5,271 +5,255	+32,844%	+$354K	0.02%	532
2024 Q4	$1.05K	Buy	16 +7	+78%	+$469	﹤0.01%	2366
2024 Q3	$633	Hold	9	–	–	﹤0.01%	2332
2024 Q2	$741	Hold	9	–	–	﹤0.01%	1414
2024 Q1	$786	Buy	+9	New	+$806	﹤0.01%	2264
2022 Q4	$19.8K	Sell	191 -17,741	-99%	-$1.67M	﹤0.01%	1309
2022 Q3	$1.52M	Buy	17,932 +17,847	+20,996%	+$1.59M	0.13%	145
2022 Q2	$7K	Buy	+85	New	+$6.77K	﹤0.01%	1555
2022 Q1	–	Sell	-100	Closed	-$9K	–	728
2021 Q4	$9K	Buy	+100	New	+$8.25K	﹤0.01%	1572

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

CoreCap Advisors's BMRN Position: Q2 2026 in Review

CoreCap Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 188% in Q2 2026, buying an estimated $822 and bringing the position to 23 shares worth $1.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2635.

CoreCap Advisors first reported a position in BMRN in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.52M in Q3 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

CoreCap Advisors held 23 shares of BioMarin Pharmaceuticals worth $1.32K as of Q2 2026.
CoreCap Advisors bought 15 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $822.
BioMarin Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2635 holding.
CoreCap Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 14 quarters since.
CoreCap Advisors's BioMarin Pharmaceuticals position peaked at $1.52M in Q3 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.